10-K: InnovAge Reports Increased Net Loss Amid Revenue Growth & Legal Costs

Sentiment:

Annual Report 9 September 2025 5:06 PM

InnovAge Holding Corp. reported an 11.8% revenue increase to $853.7 million in fiscal year 2025, but net loss widened to $35.3 million due to impairments and legal settlements.

Delay expectedExperienced delays and increased gaps in eligibility for new enrollments and Medicaid redetermination applications, particularly in California.The California Department of Health Care Services (DHCS) suspended state-required attestations for planned de novo centers in Downey and Bakersfield, California, due to deficiencies in the Sacramento center and an ongoing medical review in the San Bernardino center.The One Big Beautiful Bill Act (OBBBA) generally requires bi-annual Medicaid eligibility verifications, which may increase enrollment delays due to insufficient staffing to handle the higher volume of work.

Worse than expectedNet loss increased significantly to $35.3 million in fiscal year 2025 from $23.2 million in fiscal year 2024, representing a 52% increase in loss.Operating loss also increased to $29.8 million in fiscal year 2025 from $23.2 million in fiscal year 2024.The company incurred substantial impairment charges and losses on assets held for sale totaling $13.6 million, primarily due to abandoning a planned de novo center in Louisville, Kentucky.An additional $10.1 million was accrued as the company's share for the settlement of a securities class action lawsuit, contributing to the increased loss.Cost of care, excluding depreciation and amortization, increased by 17.5%, outpacing the 11.8% revenue growth, indicating rising operational expenses relative to revenue.

Summary

InnovAge is the largest Program of All-Inclusive Care for the Elderly (PACE) provider in the U.S., serving approximately 7,740 participants across 20 centers in six states as of June 30, 2025.
Total revenues increased by 11.8% to $853.7 million for the fiscal year ended June 30, 2025, up from $763.9 million in the prior year.
This revenue growth was driven by a 10.3% increase in member months and a 1.4% increase in capitation rates.
Net loss widened to $35.3 million in fiscal year 2025, compared to a net loss of $23.2 million in fiscal year 2024.
Operating loss increased to $29.8 million in fiscal year 2025 from $23.2 million in fiscal year 2024.
Adjusted EBITDA significantly increased by 109% to $34.5 million in fiscal year 2025, with the Adjusted EBITDA margin improving to 4.0% from 2.2%.
External provider costs rose by 7.0% to $431.2 million, primarily due to increased member months, partially offset by a 3.0% decrease in cost per participant.
Cost of care, excluding depreciation and amortization, increased by 17.5% to $268.9 million, driven by higher salaries, wages, benefits, and operational expenses.
The company incurred $13.6 million in impairments and loss on assets held for sale, mainly from halting a planned de novo center in Louisville, Kentucky.
InnovAge accrued $10.1 million as its share for the settlement of a securities class action lawsuit in June 2025.
The company acquired certain pharmacy assets from Tabula Rasa HealthCare Group (TRHC) for $4.8 million in January 2025 to support growth and improve pharmacy cost-management.
A joint venture with Tampa General Hospital was entered into in August 2025 to develop the Tampa PACE center.
InnovAge is subject to ongoing civil investigative demands from the Colorado Attorney General and the Department of Justice (DOJ) under the False Claims Act regarding Medicaid billing, patient services, referrals, and relationships with residential care facilities.

Sentiment

Score: 4

Explanation: While revenue growth and Adjusted EBITDA showed strong improvement, the significant increase in net loss, substantial impairment charges, and legal settlement costs indicate underlying challenges. Regulatory hurdles, particularly the suspension of de novo center attestations in California and the potential negative impact of the OBBBA on Medicaid funding, present considerable headwinds. The company is investing in growth and efficiency, but these efforts are currently offset by rising costs and legal expenses.

Positives

Achieved strong total revenue growth of 11.8% to $853.7 million in fiscal year 2025, driven by increased participant enrollment and capitation rates.
Reported a significant 109% increase in Adjusted EBITDA to $34.5 million, with the Adjusted EBITDA margin improving to 4.0% from 2.2% in the prior year.
Successfully increased participant census by 10.3% in fiscal year 2025, reaching approximately 7,740 participants.
Maintained high participant satisfaction with an I-SAT Net Promoter Score (NPS) of 56 in fiscal year 2025, which compares favorably to a national PACE program average of 55.
Demonstrated strong participant retention with a low voluntary disenrollment rate, averaging 7.0% annually over the last three fiscal years.
Experienced a 3.0% decrease in external provider cost per participant, partly due to the transition to in-house pharmacy services and reduced inpatient/nursing facility utilization.
Completed the acquisition of pharmacy assets from TRHC, aiming to support growth and improve pharmacy cost-management.
Entered into a new joint venture with Tampa General Hospital in August 2025, expanding strategic partnerships.
Refinanced the Term Loan Facility and renewed the Revolving Credit Facility, extending maturity dates to August 2028, enhancing liquidity and capital structure.
Reported high employee engagement, with 82% of employees indicating pride in working at InnovAge in January 2025, and a voluntary retention rate of 69%.

Negatives

Net loss widened significantly by 52% to $35.3 million in fiscal year 2025, compared to $23.2 million in fiscal year 2024.
Operating loss increased to $29.8 million in fiscal year 2025 from $23.2 million in fiscal year 2024.
Incurred $13.6 million in impairments and loss on assets held for sale, primarily due to halting development of a planned de novo center in Louisville, Kentucky.
Accrued $10.1 million as the company's share for the settlement of a securities class action lawsuit in June 2025.
Cost of care, excluding depreciation and amortization, increased by 17.5%, outpacing revenue growth, driven by higher salaries, wages, benefits, and other operational expenses.
Experienced delays and increased gaps in eligibility for new enrollments and Medicaid redetermination applications, particularly in California, leading to lower estimated per member, per month (PMPM) amounts and increased risk of revenue recovery.
The California Department of Health Care Services (DHCS) suspended state-required attestations for planned de novo centers in Downey and Bakersfield, California, hindering growth.
Ongoing civil investigative demands from the Colorado Attorney General and the DOJ under the Federal False Claims Act pose potential for significant losses or penalties.
The One Big Beautiful Bill Act (OBBBA) mandates significant reductions in federal Medicaid spending and introduces new work requirements, potentially reducing funding and decreasing margins.
The company's common stock is thinly traded, which can lead to wider spreads and less liquidity for investors.

Risks

The growth strategy may not be viable, including challenges in recruiting and retaining participants, finding suitable geographies for new centers, and obtaining necessary licenses.
Inability to successfully identify, complete, and integrate acquisitions, joint ventures, and other strategic partnerships, including navigating regulatory approvals and managing new market challenges.
Ongoing macroeconomic and industry-related challenges, such as labor shortages, labor competition, high inflation, tariffs, and trade disputes, could continue to impact business operations and results.
Regular inspections, reviews, audits, and investigations by federal and state government programs may result in adverse findings, corrective actions, enrollment sanctions, refunds, fines, or exclusion from programs.
Exposure to legal proceedings, enforcement actions, litigation, malpractice, and privacy disputes, which are costly to defend and could materially harm the business and results of operations.
Under PACE contracts, the company assumes all risk that the cost of providing services will exceed compensation, potentially leading to losses if medical costs increase unexpectedly.
Expected continued increases in costs and expenditures due to growth investments, transformation initiatives, compliance costs, and public company expenses, which may not be offset by sufficient revenue growth.
High dependence on a limited number of government payors (Medicare and Medicaid), making the company susceptible to reductions in budget appropriations, renegotiations, or contract terminations.
Reductions in PACE reimbursement rates or changes in program rules, including those from the OBBBA and Medicare sequestration, could materially adversely affect financial condition and results of operations.
Records and submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores, potentially leading to repayment obligations or penalties under the False Claims Act.
Failure to adhere to complex and changing government laws and regulations (e.g., Anti-Kickback Statute, Stark Law, False Claims Act, HIPAA, corporate practice of medicine laws) could result in severe consequences.
The Principal Shareholders control approximately 83% of common stock, and their interests may conflict with those of other shareholders.
Operating results may fluctuate significantly, making future results difficult to predict and potentially causing results to fall below guidance or investor expectations.
Security breaches, loss of data, and other disruptions could compromise sensitive information, expose the company to liability, and adversely affect business and reputation.
Inaccurate estimation of incurred but not reported medical expenses could adversely affect results of operations.
Risks related to lease termination, lease expense escalators, and inability to renew or extend leases for centers.
Adverse effects on business from pandemics, epidemics, outbreaks of infectious diseases, severe weather events, or other factors beyond control.
Inability to effectively adapt to changes in the healthcare industry, including U.S. healthcare reform and new regulations.
Laws regulating the corporate practice of medicine could restrict business operations and lead to penalties or restructuring.
Existing indebtedness could adversely affect the business, including exposure to interest rate fluctuations and restrictive covenants.
Inability to raise additional capital or generate sufficient cash flows could reduce competitiveness and harm results of operations.
The company's common stock is thinly traded, which can lead to wider spreads, less displayed size, and difficulty selling.
Future offerings of debt or equity securities may materially adversely affect the market price of common stock and dilute existing shareholders.
Failure to comply with Nasdaq's continued listing requirements could result in delisting, affecting market price and liquidity.

Future Outlook

InnovAge anticipates increased cost of care from third-party service providers in fiscal year 2026 due to budget pressures from the One Big Beautiful Bill Act (OBBBA) and state Medicaid program cuts, as well as potential increases in medical and supply costs. The company plans to continue significant investments in business growth and transformation initiatives, including increasing its participant base, building payor sophistication, expanding through acquisitions, hiring additional employees, and improving technology. While these investments are expected to increase short-term expenses as a percentage of revenue, they are projected to positively impact the business and results of operations in the longer term. The National PACE Association targets a 27% compound annual growth rate for PACE enrollment over the next four years, presenting a substantial market opportunity, though this is subject to macroeconomic and regulatory changes, particularly the OBBBA's potential negative impact on Medicaid funding and enrollment. CMS's expanded RADV auditing will also increase compliance burden and potential for recoupment.

Management Comments

Our programs are designed to address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes.
We believe our model aligns with how healthcare is evolving, namely (i) the shift toward value-based care, (ii) eliminating excessive administrative costs by contracting directly with the government, (iii) focusing on the patient experience, and (iv) addressing social determinants of health.
We believe our vertically integrated model can deliver better health outcomes and reduce unnecessary or avoidable medical spend.
Our people are our product at InnovAge, and their commitment to our participants propels our mission of enabling seniors to age at home, with dignity, for as long as is safely possible.
We believe that our ongoing investment in the InnovAge Platform drives greater efficiency across our business, creating a virtuous cycle that allows us to continue providing necessary care to our participants.
We plan to continually invest in technology improvements and seek to unlock new insights through enhanced data analytics capabilities that will advance our care model.
We are investing in building capabilities to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends.
In the long-term, we intend to reduce medical costs in order to generate savings for reinvestment to support continuous improvement of the InnovAge Platform.
We view the government not only as a payor but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets.
Maintaining, supporting and growing these relationships, in existing markets as well as new geographies, is critical to our long-term success.

Industry Context

The U.S. healthcare industry is grappling with rapidly rising costs, projected to accelerate due to an aging population, with dual-eligible seniors incurring significantly higher expenses. InnovAge's PACE model directly addresses this by offering a value-based, capitated care approach that aims to reduce costs and improve outcomes, aligning with the industry's shift away from fee-for-service models. The COVID-19 pandemic further underscored the need for integrated care delivery, a strength of InnovAge's model. However, the industry faces persistent labor shortages, particularly in geriatric and direct care roles, exacerbated by high inflation, leading to increased wage pressures. Regulatory scrutiny of healthcare transactions is intensifying, and legislative changes like the One Big Beautiful Bill Act (OBBBA) are poised to significantly impact Medicaid funding and eligibility, creating an uncertain operating environment for providers like InnovAge.

Comparison to Industry Standards

InnovAge's PACE model is estimated to be 12% lower on average in cost compared to a comparable dual-eligible population aged 65 and older under Medicaid, based on a January 2024 analysis by the National PACE Association, indicating cost-effectiveness.
InnovAge's participants demonstrated a lower hospital readmission rate compared to a frail, dual-eligible or disabled waiver population as of June 30, 2025, suggesting superior health outcomes.
The company's I-SAT Net Promoter Score (NPS) of 56 in fiscal year 2025 compares favorably to a national PACE program average of 55, indicating above-average participant satisfaction within its specific industry segment.
InnovAge is the largest PACE provider in the United States by number of participants (7,740 as of June 30, 2025), being 16% larger than its closest PACE-focused competitor and more than 30 times larger than the typical PACE operator, demonstrating a dominant market position.
InnovAge participants are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in average Medicare Advantage (MA) programs, with an average Medicare Risk Adjustment Factor (RAF) score of 2.42 as of June 30, 2025, indicating management of a higher-acuity population.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Anti-Takeover Provisions	The certificate of incorporation, bylaws, and Delaware General Corporation Law (DGCL) contain provisions intended to enhance Board continuity and stability, avoid costly takeover battles, and reduce vulnerability to hostile change of control. These include a classified board, restrictions on shareholder action by written consent (when Principal Shareholders own less than 35% voting power), limitations on calling special shareholder meetings, and advance notice procedures for shareholder proposals and director nominations.	Ongoing	May delay, deter, or prevent a merger or acquisition that shareholders might consider in their best interest, potentially limiting opportunities for a premium over market price.
Director Removal and Vacancies	Prior to Principal Shareholders owning less than 40% of outstanding common stock, directors may be removed with or without cause by a majority vote. After this threshold, directors may only be removed for cause by an affirmative vote of at least 66 2/3% of voting power. Newly created directorships and vacancies are filled by a majority of directors in office, not by shareholders.	Ongoing	Makes it more difficult for shareholders to change the composition of the Board and effect a change in management.
Supermajority Approval Requirements	From and after the date on which Principal Shareholders beneficially own less than 50% of outstanding common stock, amending, altering, rescinding, or repealing bylaws or certain certificate of incorporation provisions requires an affirmative vote of at least 66 2/3% of voting power. Amending the corporate opportunity provision requires an 80% supermajority vote.	Ongoing	Increases the difficulty for existing shareholders to replace the Board or for another party to obtain control by replacing the Board, and could make it harder to effect changes in management.
Authorized but Unissued Shares	Authorized but unissued shares of common and preferred stock are available for future issuance without shareholder approval, subject to stock exchange rules.	Ongoing	May enable the Board to issue shares to persons friendly to current management, potentially rendering more difficult or discouraging attempts to obtain control of the company.
Business Combinations	The company opted out of Section 203 of the DGCL but has similar provisions in its certificate of incorporation prohibiting certain business combinations with interested shareholders for a three-year period, unless Board or supermajority shareholder approval is obtained. Principal Shareholders are excluded from being considered interested shareholders.	Ongoing	May make it more difficult for a person who would be an interested shareholder to effect various business combinations and may encourage negotiation with the Board, potentially preventing changes in the Board and transactions shareholders might deem beneficial.
Forum Selection	The certificate of incorporation designates the Court of Chancery of the State of Delaware (or U.S. District Court for District of Delaware) as the exclusive forum for certain litigation, and federal district courts of the U.S. as the exclusive forum for Securities Act claims.	Ongoing	May discourage lawsuits against the company or its directors and officers and limit shareholders' ability to obtain a favorable judicial forum for disputes.
Conflicts of Interest	The certificate of incorporation renounces any interest or expectancy in specified business opportunities presented to Principal Shareholders or non-employee directors or their affiliates, allowing them to pursue such opportunities, unless expressly offered to a non-employee director solely in their capacity as a company director or officer.	Ongoing	Allows Principal Shareholders and non-employee directors to engage in activities that may conflict with the company's interests, potentially diverting business opportunities.
Limitations on Liability and Indemnification	The certificate of incorporation eliminates personal liability of directors and officers for monetary damages for breaches of fiduciary duty, except for bad faith or intentional violations. Bylaws provide for indemnification and advancement of expenses to the fullest extent authorized by DGCL.	Ongoing	May discourage shareholders from bringing lawsuits against directors or officers for breaches of fiduciary duties and could reduce the likelihood of derivative litigation.
Controlled Company Status	The company is a controlled company under Nasdaq rules due to Principal Shareholders controlling a majority of voting power, allowing it to rely on exemptions from certain corporate governance requirements (e.g., majority independent board, independent committees).	Ongoing	Shareholders do not have the same protections afforded to shareholders of companies subject to all Nasdaq governance requirements.
Cybersecurity Program Oversight	The Audit Committee monitors cybersecurity risks, with the CIO and CISO providing quarterly briefings. An Information Security Team, with experienced members and certifications, is responsible for the program's oversight and operation.	Ongoing	A structured approach to managing cybersecurity risks, aiming to enhance resilience and protection of sensitive information.
Code of Ethics	A written Code of Ethics applies to directors, executive officers, and employees, including those responsible for financial reporting.	Ongoing	Promotes ethical conduct and compliance with legal and regulatory requirements.

Legal Proceedings

Civil Investigative Demand from the Attorney General for the State of Colorado (July 2021) under the Colorado Medicaid False Claims Act, requesting information on Medicaid billing, patient services, and referrals in Colorado. The company is cooperating, but possible losses are currently inestimable.
Civil Investigative Demand from the Department of Justice (DOJ) (February 2022) under the Federal False Claims Act, requesting information on audits, billing, orders tracking, and quality/timeliness of patient services across states of operation. A supplemental demand was received in December 2022. Discussions with the DOJ have begun, but possible losses are currently inestimable.
Civil Investigative Demand from the DOJ (October 2024) under the Federal False Claims Act, requesting information on the company's relationship with residential care facilities, housing costs, and enrollment practices in California, Colorado, Virginia, and New Mexico. The company is cooperating, but possible losses are currently inestimable.
Securities Class Action Lawsuit (October 14, 2021) alleging violations of the Securities Act and Exchange Act related to the IPO and public filings. The company and other defendants entered a settlement agreement in June 2025 for $27.0 million, with InnovAge's share being $10.1 million. Preliminary approval was granted on June 17, 2025, with a final approval hearing set for November 26, 2025.
Stockholder Derivative Lawsuit (May 15, 2023, filed by Brian Hall) asserting breach of fiduciary duty claims against current and former officers and directors, related to alleged failures to address CMS sanctions and misstatements in public filings. The litigation is stayed, and parties are discussing a potential resolution as of July 11, 2025. Possible losses are currently inestimable.
Arbitration Proceeding (June 16, 2025, filed by Grane Supply, Inc.) against the company, asserting claims for breach of contract and confidentiality related to the non-renewal and termination of pharmacy services agreements. A final merits hearing is expected in early 2026. Possible losses are currently inestimable.

Related Party Transactions

Ignite Aggregator LP (Apax Partners) and funds affiliated with Welsh, Carson, Anderson and Stowe (WCAS) (collectively, the Principal Shareholders) beneficially own approximately 83% of the company's common stock, giving them significant control over corporate decisions.
The company is party to a Director Nomination Agreement with the Principal Shareholders, granting them rights to designate nominees for the Board of Directors and certain consent rights.
The company's certificate of incorporation allows the Principal Shareholders and their affiliates to engage in business activities that may compete with the company and pursue business opportunities that may not be available to InnovAge.
The company's certificate of incorporation's business combination provisions specifically exclude the Principal Shareholders from being considered 'interested shareholders'.
TCO Group Holdings, L.P. (the LP), the company's largest shareholder and prior parent, maintains the 2020 Equity Incentive Plan, under which profits interests units are granted to employees, directors, consultants, and advisers of the LP or its affiliates, including InnovAge.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings, market price volatility, and the significant influence of Principal Shareholders on corporate decisions. The company's status as a controlled company also means fewer corporate governance protections.
Participants benefit from improved quality of care, lower hospital readmission rates, and high satisfaction (I-SAT NPS of 56). However, they may experience service disruptions due to regulatory sanctions or delays in enrollment/redetermination, and potential impacts from the OBBBA on Medicaid benefits.
Employees benefit from increased headcount, higher wage rates, and training programs, reflected in high employee engagement and a 69% voluntary retention rate. However, labor shortages and competition in the healthcare sector create ongoing pressure.
Government payors (Medicare and Medicaid) benefit from fiscal certainty through capitated payments and lower costs associated with the PACE program. However, they are subject to government budget cuts (e.g., OBBBA) and changes in reimbursement rates.
Suppliers and vendors may face supply chain disruptions, higher prices for medical supplies, and potential disputes, as evidenced by the ongoing arbitration with Grane Rx.
Creditors are impacted by the company's indebtedness, including variable interest rates and restrictive covenants in credit agreements, with potential for acceleration of debt in case of default.

Next Steps

Continue efforts to increase participant enrollment and capacity within existing centers.
Ramp up newer de novo centers in Florida (Tampa and Orlando).
Prioritize target markets for future de novo developments.
Pursue tuck-in acquisitions, strategic transactions, and partnerships, including the joint venture with Tampa General Hospital.
Reinvest in the InnovAge Platform to optimize performance, including technology improvements and enhanced data analytics capabilities.
Build capabilities to increase sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends.
Remediate deficiencies identified in the Sacramento center and complete the medical review in the San Bernardino center to reinstate state attestations for California de novo centers.
Continue full cooperation with the Colorado Attorney General and the DOJ regarding civil investigative demands and engage in discussions to understand their respective positions.
Await the final approval hearing for the securities class action settlement on November 26, 2025.
Continue discussions for a potential resolution of the stockholder derivative lawsuit.
Prepare for the final merits hearing in early 2026 for the Grane Rx arbitration.
Adjust administrative processes to ensure compliance with new OBBBA requirements, including more frequent Medicaid eligibility verifications.
Monitor the full scope of the impact of the OBBBA and other policy changes on the business.
Evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Expense Disaggregation Disclosures) on consolidated financial statements.

Key Dates

Date	Description
May 2007	Total Community Options, Inc. d/b/a InnovAge formed.
May 13, 2016	InnovAge Holding Corp. and certain wholly owned subsidiaries formed as for-profit corporations.
March 2021	Initial Public Offering (IPO) and company name change to InnovAge Holding Corp.
March 8, 2021	Director Nomination Agreement and Credit Agreement entered into.
April 1, 2013	Medicare payment sequestration by two percent per year began, extended through fiscal year 2032.
October 14, 2021	Company named as defendant in a putative class action complaint (Securities Action).
April 20, 2022	Board received a books and records demand from a purported stockholder, Brian Hall.
February 2022	Company received a civil investigative demand from the Department of Justice (DOJ) under the Federal False Claims Act.
December 2022	Company received a supplemental civil investigative demand from the DOJ.
February 1, 2023	CMS published the Medicare Advantage RADV Program Final Rule, effective April 3, 2023.
May 15, 2023	Brian Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims.
December 1, 2023	Acquisition of ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC completed.
January 22, 2024	Court entered an order further staying the Hall v. InnovAge litigation.
March 13, 2024	Pinewood Lodge, LLLP (PWD) entered into a Purchase and Sale Agreement for its property.
May 2, 2024	PWD closed on the sale of its Senior Housing property and was dissolved.
May 21, 2025	CMS announced a significant expansion of its RADV auditing, with all eligible MA plans to be audited annually.
May 28, 2024	Joint Venture Agreement with Orlando Health entered into for InnovAge Florida PACE Orlando.
June 10, 2024	Board announced approval of a share repurchase program authorizing up to $5 million.
September 26, 2024	Board authorized an additional $2.5 million for the share repurchase program.
October 2024	Company received a civil investigative demand from the DOJ under the Federal False Claims Act on similar subject matter as the 2022 investigation.
October 31, 2024	Amended Employment Agreements with Patrick Blair and Michael Scarbrough.
November 4, 2024	Class B Unit Award Agreement with Michael Scarbrough.
January 1, 2025	Updated PACE Medicaid Capitation Rate Settling Guide became effective.
January 2, 2025	Acquisition of certain pharmacy assets from Tabula Rasa HealthCare Group (TRHC) completed.
January 15, 2025	Minimum False Claims Act penalty increased from $13,946 to $14,308 per claim, and maximum from $27,894 to $28,619 per claim.
January 2025	Most recent employee engagement survey conducted.
June 2025	Company and other defendants entered into a settlement agreement for the securities class action lawsuit for $27.0 million.
June 16, 2025	Grane Supply, Inc. filed an amended demand for arbitration against the Company.
June 17, 2025	Securities class action settlement agreement received preliminary approval from the District Court.
June 30, 2025	End of fiscal year. Company entered into an agreement to sell its managing member interest in InnovAge Senior Housing Thornton, LLC (SH1) and adjacent vacant land.
July 4, 2025	The One Big Beautiful Bill Act (OBBBA) was enacted in the U.S.
July 11, 2025	Parties informed the Court of the settlement agreement in the Securities Action and requested an update by September 10, 2025, for the Hall v. InnovAge litigation.
August 8, 2025	Amendment No. 2 to the Credit Agreement entered, refinancing the Term Loan Facility and renewing the Revolving Credit Facility.
August 15, 2025	Joint Venture Agreement with Tampa General Hospital entered into to develop the Tampa PACE center.
September 2, 2025	135,637,975 shares of common stock outstanding.
September 5, 2025	Class B Unit Award Agreements granted to Patrick Blair, Benjamin C. Adams, and Nicole DAmato.
September 9, 2025	Date of filing of the Annual Report on Form 10-K.
September 30, 2025	Medicare telehealth flexibilities implemented during COVID-19 pandemic extended through this date.
November 26, 2025	Final approval hearing set for the securities class action settlement.
Early 2026	Final merits hearing in front of the arbitrator expected for the Grane Rx arbitration.
December 15, 2025	ASU 2023-09 (Income Taxes) effective for annual periods beginning after this date.
June 30, 2026	Expected date for the company to no longer qualify as an emerging growth company.
December 15, 2026	ASU 2024-03 (Expense Disaggregation Disclosures) effective for annual reporting periods beginning after this date.
August 8, 2028	Extended maturity date for the Term Loan A Facility and Revolving Credit Facility.
August 20, 2030	Maturity date for the convertible term loan.
Fiscal Year 2032	Medicare benefit payment sequestration extended through this fiscal year.
2037	State net operating loss carryforwards begin to expire.

Recommendation

hold

InnovAge demonstrates strong revenue growth and improved Adjusted EBITDA, indicating operational efficiency gains in its core PACE model. Participant satisfaction and retention are high, and the company is strategically expanding through acquisitions and de novo centers. However, the significant increase in net loss, substantial impairment charges, and the $10.1 million securities class action settlement raise concerns about GAAP profitability and past operational issues. The ongoing civil investigative demands from the DOJ and Colorado AG, coupled with regulatory hurdles like the suspended California de novo attestations, introduce considerable uncertainty and potential future liabilities. Furthermore, the One Big Beautiful Bill Act poses a significant risk to Medicaid funding and participant enrollment, which could impact future margins. While the long-term value-based care model is promising, these current legal, regulatory, and financial headwinds suggest a 'Hold' recommendation until there is greater clarity on the resolution of these issues and the full impact of legislative changes. The stock's thinly traded nature also adds to volatility risk.

Keywords

PACE, Program of All-Inclusive Care for the Elderly, Healthcare, Seniors, Dual-eligible, Value-based care, Medicare, Medicaid, SEC filing, 10-K, InnovAge, INNV, Capitation, Risk adjustment, Elderly care, Managed care, Health outcomes, Care coordination, Regulatory compliance, False Claims Act, Anti-Kickback Statute, HIPAA, Financial performance, Net Promoter Score, Acquisitions, Joint ventures, De novo centers, Share repurchase, Corporate governance, Legal proceedings, Cybersecurity, One Big Beautiful Bill Act

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.